Phoenix, March 26, 2018 --
Premier Biomedical Inc., (OTC: BIEI) ("the Company"), today reviewed recent accomplishments in interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
Premier Biomedical consists of two divisions, one focused on biologics and the other on topical pain relief products. The pain relief division is revenue-generating and has grown from one product a year ago, to five products today, distributed through the company’s website, www.painreliefmeds.com, and by a number of regional pharmacies and an on-line pharmacy, HealthWarehouse.com.
“Last time we spoke, you were delving into the process of sales for your many products,” said Jolly. “Also, you have been working diligently in becoming financially independent, can you expand on that?”
“We came out with five new pain relief products in 2017, and now have hired a national sales director and three sales managers. Additionally, we are working with retired NFL players, which has led to an expansion into a new line of enhanced Sports Strength pain relievers,” Hartman commented. “I think the progress we have made with the pain relief products is going to make us financially independent in this calendar year.”
To listen to the full interview please click here to the following link:
About Premier Biomedical Inc.
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop extracorporeal treatments for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, Anti-aging and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market..
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Source: Uptick Newswire
For further information please contact: William A. Hartman President and CEO Premier Biomedical Inc. (724) 633-7033 [email protected] www.premierbiomedical.com


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anta Sports Expands Global Footprint With Strategic Puma Stake
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



